# Kuros Biosciences Raises 2026 Outlook Following 40% Sales Growth

- URL: https://stocks.freetheai.org/news/kuros-biosciences-raises-2026-outlook-following-40-sales-growth-b21b0a
- Published: 2026-10-15T05:00:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [BX:YTSN](https://stocks.freetheai.org/symbols/BX-YTSN)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Kuros Biosciences Ltd. (BX:YTSN) upgraded its full-year 2026 guidance for revenue growth and adjusted EBITDA. The higher targets follow a 40% year-over-year increase in sales during the first nine months of 2026, alongside record adjusted EBITDA. Shares traded up 2.85% to 18.58 CHF following the update.

The growth highlights strong product demand and expanding operating leverage. To sustain momentum without production constraints, the company activated a second manufacturing facility in Georgia, adding capacity to secure supply lines.

Looking forward, investors will track concrete full-year revenue figures and margin milestones. Progress and clinical readouts from three Level I trials currently enrolling patients will also serve as important catalysts for further market adoption.

## Key points

- Kuros Biosciences raised its full-year 2026 revenue growth and adjusted EBITDA guidance.
- Sales grew 40% year-over-year during the first nine months of 2026, achieving record adjusted EBITDA.
- The company activated a second manufacturing plant in Georgia to expand production capacity.
- Three Level I clinical trials are actively enrolling patients to support product validation.
- Shares of Kuros Biosciences Ltd. (BX:YTSN) rose 2.85% to 18.58 CHF.

## Questions and answers

### Why did Kuros Biosciences raise its 2026 guidance?

Kuros Biosciences raised its full-year 2026 outlook after reporting a 40% year-over-year increase in sales and record adjusted EBITDA through the first nine months of the year.

### What operational expansions has Kuros Biosciences completed?

The company activated a second manufacturing facility in Georgia to increase capacity and prevent supply bottlenecks.

### What upcoming catalysts should investors watch for Kuros Biosciences?

Key catalysts include enrollment progress and results from three active Level I clinical trials, as well as concrete full-year revenue and margin targets.